Long-Term Outcomes in SLE at Peking University People's Hospital
Recruiting · NCT07005479 · Observational (researchers observe without assigning treatment) · Lead sponsor: Peking University People's Hospital
View the official record on ClinicalTrials.gov →What this trial is about
This study aims to prospectively follow patients diagnosed with Systemic Lupus Erythematosus (SLE) at Peking University People's Hospital, assessing long-term outcomes such as disease activity, organ involvement, survival, and quality of life. Findings will support individualized patient management and contribute to understanding disease progression in the Chinese population.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- All patients must meet at least one of the following classification criteria for Systemic Lupus Erythematosus (SLE):
- The 1997 American College of Rheumatology (ACR) Revised Classification Criteria; The 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria; The 2019 EULAR/ACR Classification Criteria for SLE. All patients must be over the age of 18 and competent to provide written consent.
Exclusion criteria
- Patients less than 18 years of age and patients who are unable to consent are excluded from the study.
Where it is running
1 location listed.
- Department of Rheumatology and Immunology, Peking University People's Hospital - Beijing, Beijing Municipality, China